You are here

SARC020

Active
A Phase IIb/III multicenter study comparing the efficacy of trabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
Type of Sarcoma: 
advanced or metastatic untreated soft tissue sarcoma
Drug: 
trabectedin infused to doxorubicin
Accrual Status: 
Open, Not Accruing
Overall Study Principal Investigator: 
James E. Butrynski, MD
Dana-Farber Cancer Institute

For more information about this trial and open sites: